Alzheimer disease models and human neuropathology: similarities and differences
Top Cited Papers
Open Access
- 16 November 2007
- journal article
- review article
- Published by Springer Nature in Acta Neuropathologica
- Vol. 115 (1) , 5-38
- https://doi.org/10.1007/s00401-007-0312-8
Abstract
Animal models aim to replicate the symptoms, the lesions or the cause(s) of Alzheimer disease. Numerous mouse transgenic lines have now succeeded in partially reproducing its lesions: the extracellular deposits of Aβ peptide and the intracellular accumulation of tau protein. Mutated human APP transgenes result in the deposition of Aβ peptide, similar but not identical to the Aβ peptide of human senile plaque. Amyloid angiopathy is common. Besides the deposition of Aβ, axon dystrophy and alteration of dendrites have been observed. All of the mutations cause an increase in Aβ 42 levels, except for the Arctic mutation, which alters the Aβ sequence itself. Overexpressing wild-type APP alone (as in the murine models of human trisomy 21) causes no Aβ deposition in most mouse lines. Doubly (APP × mutated PS1) transgenic mice develop the lesions earlier. Transgenic mice in which BACE1 has been knocked out or overexpressed have been produced, as well as lines with altered expression of neprilysin, the main degrading enzyme of Aβ. The APP transgenic mice have raised new questions concerning the mechanisms of neuronal loss, the accumulation of Aβ in the cell body of the neurons, inflammation and gliosis, and the dendritic alterations. They have allowed some insight to be gained into the kinetics of the changes. The connection between the symptoms, the lesions and the increase in Aβ oligomers has been found to be difficult to unravel. Neurofibrillary tangles are only found in mouse lines that overexpress mutated tau or human tau on a murine tau −/− background. A triply transgenic model (mutated APP, PS1 and tau) recapitulates the alterations seen in AD but its physiological relevance may be discussed. A number of modulators of Aβ or of tau accumulation have been tested. A transgenic model may be analyzed at three levels at least (symptoms, lesions, cause of the disease), and a reading key is proposed to summarize this analysis.Keywords
This publication has 357 references indexed in Scilit:
- A transgenic rat expressing human APP with the Swedish Alzheimer’s disease mutationBiochemical and Biophysical Research Communications, 2007
- Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degenerationActa Neuropathologica, 2007
- Spatial relationship between synapse loss and β‐amyloid deposition in Tg2576 miceJournal of Comparative Neurology, 2006
- Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a knock-in mouse model of familial Alzheimer's diseaseExperimental Neurology, 2006
- Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic miceNeurobiology of Aging, 2005
- Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse modelsNeurochemistry International, 2005
- Transgenic Mice Expressing Human β‐APP751, But Not Mice Expressing β‐APP695, Display Early Alzheimer's Disease‐like HistopathologyaAnnals of the New York Academy of Sciences, 1993
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's diseaseNature, 1991
- Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid proteinBiochemical and Biophysical Research Communications, 1984